On November 15, 2022, Health Canada released a new guidance document, “Guidance on clinical evidence requirements for medical devices.” In this document, Health Canada provides guidance on clinical evidence requirements for Class II, III, and IV medical devices. This document does not apply to in vitro diagnostic devices (IVDDs).
The document includes guidance on when clinical data/evidence is required, methods to generate and evaluate clinical data, and how to compare devices appropriately. It also provides general principles and criteria for clinical evidence that supports amending licence applications, and additional obligations during the post-market phase.
Health Canada also released a companion document, “Examples of clinical evidence requirements for medical devices,” which contains examples of different types of devices and outlines when clinical evidence is more likely or less likely to be required.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
PMPRB news: New Vice Chairperson appointed, Meds Entry Watch 7th Ed. published
On August 15, 2023, the Minister of Health announced the appointment of Anie Perrault as Vice Chairperson of the Patented Medicine Prices Review Board (PMPRB) for a five-year term.Read More -
Updated and new draft Health Canada guidance documents related to medical devices
On August 30, 2023, Health Canada opened consultation on its draft pre-market guidance for machine learning-enabled medical devices (MLMD).Read More -
pCPA appoints Douglas Clark as its first CEO
The pan-Canadian Pharmaceutical Alliance (pCPA) has appointed Douglas Clark as the pCPA’s first CEO, effective September 11, 2023.Read More